Susquehanna International Group
MACK

Susquehanna International Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Susquehanna International Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-132,800
Closed -$1.78M – 13879
2023
Q4 		$1.78M Buy
132,800
+15,800
+14% +$200K ﹤0.01% 5621
2023
Q3 		$1.44M Buy
117,000
+89,900
+332% +$1.09M ﹤0.01% 5815
2023
Q2 		$333K Sell
27,100
-172,300
-86% -$2.15M ﹤0.01% 9222
2023
Q1 		$2.45M Buy
199,400
+11,900
+6% +$140K ﹤0.01% 4729
2022
Q4 		$2.15M Buy
187,500
+176,300
+1,574% +$1.45M ﹤0.01% 4569
2022
Q3 		$42K Sell
11,200
-17,000
-60% -$78.5K ﹤0.01% 12314
2022
Q2 		$168K Sell
28,200
-117,200
-81% -$661K ﹤0.01% 10886
2022
Q1 		$920K Sell
145,400
-105,900
-42% -$595K ﹤0.01% 7337
2021
Q4 		$983K Buy
251,300
+176,200
+235% +$765K ﹤0.01% 7345
2021
Q3 		$363K Buy
75,100
+47,800
+175% +$249K ﹤0.01% 10153
2021
Q2 		$174K Sell
27,300
-58,200
-68% -$384K ﹤0.01% 11734
2021
Q1 		$537K Buy
85,500
+27,300
+47% +$195K ﹤0.01% 9301
2020
Q4 		$401K Sell
58,200
-6,300
-10% -$31.1K ﹤0.01% 8730
2020
Q3 		$258K Buy
+64,500
New +$237K ﹤0.01% 9004
2020
Q2 		– Sell
-18,400
Closed -$40K – 11512
2020
Q1 		$40K Sell
18,400
-19,300
-51% -$56.5K ﹤0.01% 9760
2019
Q4 		$119K Buy
37,700
+13,300
+55% +$53.3K ﹤0.01% 9062
2019
Q3 		$110K Buy
+24,400
New +$122K ﹤0.01% 9518
2018
Q4 		– Sell
-31,267
Closed -$131K – 10688
2018
Q3 		$131K Sell
31,267
-2,287
-7% -$9.64K ﹤0.01% 8491
2018
Q2 		$130K Buy
33,554
+3,685
+12% +$24.5K ﹤0.01% 8934
2018
Q1 		$189K Buy
29,869
+4,322
+17% +$35.8K ﹤0.01% 8362
2017
Q4 		$206K Buy
+25,547
New +$238K ﹤0.01% 8241
2017
Q3 		– Sell
-11,973
Closed -$117K – 10221
2017
Q2 		$117K Sell
11,973
-15,328
-56% -$313K ﹤0.01% 8614
2017
Q1 		$662K Sell
27,301
-25,331
-48% -$634K ﹤0.01% 5967
2016
Q4 		$1.69M Buy
52,632
+29,957
+132% +$1.28M ﹤0.01% 4434
2016
Q3 		$1.13M Buy
22,675
+15,888
+234% +$659K ﹤0.01% 4570
2016
Q2 		$288K Buy
6,787
+3,673
+118% +$200K ﹤0.01% 7033
2016
Q1 		$205K Sell
3,114
-2,148
-41% -$112K ﹤0.01% 7929
2015
Q4 		$327K Sell
5,262
-9,888
-65% -$696K ﹤0.01% 7519
2015
Q3 		$1.01M Buy
15,150
+1,283
+9% +$105K ﹤0.01% 5720
2015
Q2 		$1.35M Buy
13,867
+5,542
+67% +$527K ﹤0.01% 5542
2015
Q1 		$778K Sell
8,325
-15,417
-65% -$1.31M ﹤0.01% 6257
2014
Q4 		$2.11M Sell
23,742
-5,122
-18% -$373K ﹤0.01% 4363
2014
Q3 		$1.99M Sell
28,864
-3,521
-11% -$188K ﹤0.01% 4612
2014
Q2 		$1.86M Buy
32,385
+13,358
+70% +$678K ﹤0.01% 4805
2014
Q1 		$754K Buy
19,027
+6,889
+57% +$295K ﹤0.01% 6028
2013
Q4 		$510K Buy
12,138
+6,596
+119% +$191K ﹤0.01% 6660
2013
Q3 		$166K Buy
5,542
+1,576
+40% +$55.1K ﹤0.01% 7877
2013
Q2 		$210K Buy
+3,966
New +$174K ﹤0.01% 7356

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group's MACK Position: Q2 2024 in Review

Susquehanna International Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 77,397 shares — an estimated $1.14M sold.

Susquehanna International Group first reported a position in MACK in Q3 2013 and held it in 34 quarters. The position peaked at $4.36M in Q4 2013. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Susquehanna International Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 77,397 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $1.14M.
  • Susquehanna International Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 34 quarters.
  • Susquehanna International Group's Merrimack Pharmaceuticals, Inc. position peaked at $4.36M in Q4 2013.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.